CL2019000728A1 - Formas cristalinas. - Google Patents
Formas cristalinas.Info
- Publication number
- CL2019000728A1 CL2019000728A1 CL2019000728A CL2019000728A CL2019000728A1 CL 2019000728 A1 CL2019000728 A1 CL 2019000728A1 CL 2019000728 A CL2019000728 A CL 2019000728A CL 2019000728 A CL2019000728 A CL 2019000728A CL 2019000728 A1 CL2019000728 A1 CL 2019000728A1
- Authority
- CL
- Chile
- Prior art keywords
- crystalline forms
- pharmaceutical compositions
- forms
- crystal
- phosphonopropionil
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016072562 | 2016-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019000728A1 true CL2019000728A1 (es) | 2019-07-05 |
Family
ID=59923448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000728A CL2019000728A1 (es) | 2016-09-22 | 2019-03-21 | Formas cristalinas. |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10730896B2 (OSRAM) |
| EP (2) | EP3515924B1 (OSRAM) |
| JP (1) | JP7097369B2 (OSRAM) |
| KR (1) | KR102552795B1 (OSRAM) |
| CN (1) | CN109715639B (OSRAM) |
| AU (1) | AU2017331930B2 (OSRAM) |
| CA (1) | CA3037794A1 (OSRAM) |
| CL (1) | CL2019000728A1 (OSRAM) |
| CY (1) | CY1125052T1 (OSRAM) |
| DK (1) | DK3515924T3 (OSRAM) |
| EA (1) | EA201990723A1 (OSRAM) |
| ES (1) | ES2908572T3 (OSRAM) |
| HR (1) | HRP20220234T1 (OSRAM) |
| HU (1) | HUE057772T2 (OSRAM) |
| IL (1) | IL265445B2 (OSRAM) |
| LT (1) | LT3515924T (OSRAM) |
| MA (1) | MA46266B1 (OSRAM) |
| MX (1) | MX381590B (OSRAM) |
| MY (1) | MY193080A (OSRAM) |
| PH (1) | PH12019500567B1 (OSRAM) |
| PL (1) | PL3515924T3 (OSRAM) |
| PT (1) | PT3515924T (OSRAM) |
| RS (1) | RS62946B1 (OSRAM) |
| SI (1) | SI3515924T1 (OSRAM) |
| TW (1) | TWI752086B (OSRAM) |
| UA (1) | UA124073C2 (OSRAM) |
| WO (1) | WO2018055016A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3515924T3 (pl) | 2016-09-22 | 2022-04-11 | Idorsia Pharmaceuticals Ltd | Krystaliczne postacie |
| BR112019014567A2 (pt) | 2017-03-15 | 2020-02-18 | Idorsia Pharmaceuticals Ltd | Antagonista do receptor p2y12 ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de éster butílico do ácido |
| MX2023000601A (es) | 2020-07-15 | 2023-02-13 | Idorsia Pharmaceuticals Ltd | Composicion farmaceutica acuosa que comprende un antagonista del receptor p2y12. |
| EP4370525A2 (en) | 2021-07-13 | 2024-05-22 | Idorsia Pharmaceuticals Ltd | A process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl- pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1 -carboxylic acid butyl ester |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
| CA2020437A1 (en) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Cinnamamide derivative |
| JP2003502314A (ja) | 1999-06-14 | 2003-01-21 | イーライ・リリー・アンド・カンパニー | 化合物 |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| EP1578423B1 (en) | 2002-12-11 | 2010-08-18 | Bayer Schering Pharma Aktiengesellschaft | 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists |
| EP1611144B1 (en) | 2003-04-09 | 2010-09-15 | Wyeth LLC | Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| NZ568335A (en) | 2005-10-21 | 2011-07-29 | Actelion Pharmaceuticals Ltd | Piperazine derivatives as antimalarial agents |
| CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| AR063518A1 (es) | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| MX2009011089A (es) | 2007-04-23 | 2009-10-30 | Sanofi Aventis | Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12. |
| HRP20120735T1 (hr) * | 2007-11-29 | 2012-10-31 | Actelion Pharmaceuticals Ltd. | Derivati fosfonske kiseline i njihova uporaba kao antagonista p2y12 receptora |
| EP2238127B1 (en) | 2007-12-26 | 2012-08-15 | Sanofi | Pyrazole-carboxamide derivatives as p2y12 antagonists |
| WO2009080226A2 (en) | 2007-12-26 | 2009-07-02 | Sanofis-Aventis | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| ES2567311T3 (es) | 2009-04-08 | 2016-04-21 | Actelion Pharmaceuticals Ltd. | 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP |
| JP5536876B2 (ja) | 2009-04-22 | 2014-07-02 | アクテリオン ファーマシューティカルズ リミテッド | チアゾール誘導体及びｐ２ｙ１２受容体拮抗剤としてのそれらの使用 |
| PL3515924T3 (pl) | 2016-09-22 | 2022-04-11 | Idorsia Pharmaceuticals Ltd | Krystaliczne postacie |
| BR112019014567A2 (pt) | 2017-03-15 | 2020-02-18 | Idorsia Pharmaceuticals Ltd | Antagonista do receptor p2y12 ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de éster butílico do ácido |
| MX2023000601A (es) | 2020-07-15 | 2023-02-13 | Idorsia Pharmaceuticals Ltd | Composicion farmaceutica acuosa que comprende un antagonista del receptor p2y12. |
-
2017
- 2017-09-21 PL PL17771436T patent/PL3515924T3/pl unknown
- 2017-09-21 PH PH1/2019/500567A patent/PH12019500567B1/en unknown
- 2017-09-21 MA MA46266A patent/MA46266B1/fr unknown
- 2017-09-21 TW TW106132387A patent/TWI752086B/zh active
- 2017-09-21 CN CN201780057793.2A patent/CN109715639B/zh active Active
- 2017-09-21 RS RS20220163A patent/RS62946B1/sr unknown
- 2017-09-21 US US16/335,973 patent/US10730896B2/en active Active
- 2017-09-21 SI SI201731102T patent/SI3515924T1/sl unknown
- 2017-09-21 MX MX2019003093A patent/MX381590B/es unknown
- 2017-09-21 EP EP17771436.7A patent/EP3515924B1/en active Active
- 2017-09-21 CA CA3037794A patent/CA3037794A1/en active Pending
- 2017-09-21 HU HUE17771436A patent/HUE057772T2/hu unknown
- 2017-09-21 MY MYPI2019001474A patent/MY193080A/en unknown
- 2017-09-21 AU AU2017331930A patent/AU2017331930B2/en active Active
- 2017-09-21 KR KR1020197011330A patent/KR102552795B1/ko active Active
- 2017-09-21 EA EA201990723A patent/EA201990723A1/ru unknown
- 2017-09-21 ES ES17771436T patent/ES2908572T3/es active Active
- 2017-09-21 EP EP21206477.8A patent/EP3981774A1/en not_active Withdrawn
- 2017-09-21 JP JP2019536696A patent/JP7097369B2/ja active Active
- 2017-09-21 IL IL265445A patent/IL265445B2/en unknown
- 2017-09-21 LT LTEPPCT/EP2017/073858T patent/LT3515924T/lt unknown
- 2017-09-21 DK DK17771436.7T patent/DK3515924T3/da active
- 2017-09-21 WO PCT/EP2017/073858 patent/WO2018055016A1/en not_active Ceased
- 2017-09-21 UA UAA201903751A patent/UA124073C2/uk unknown
- 2017-09-21 PT PT177714367T patent/PT3515924T/pt unknown
- 2017-09-21 HR HRP20220234TT patent/HRP20220234T1/hr unknown
-
2019
- 2019-03-21 CL CL2019000728A patent/CL2019000728A1/es unknown
-
2020
- 2020-07-24 US US16/938,730 patent/US11365209B2/en active Active
-
2022
- 2022-03-09 CY CY20221100195T patent/CY1125052T1/el unknown
- 2022-05-10 US US17/741,427 patent/US12227532B2/en active Active
-
2025
- 2025-01-17 US US19/028,423 patent/US20250163086A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2017005555A (es) | Composiciones de acido obeticolico y metodos de uso | |
| MX2019002049A (es) | Compuestos de pirrolizina sustituidos y usos de los mismos. | |
| CO2018004124A2 (es) | Compuestos heterocíclicos | |
| CL2017000786A1 (es) | Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos. | |
| BR112017013491A2 (pt) | compostos de pirimidina fundida para o tratamento de hiv | |
| CU20180001A7 (es) | Derivados de oxopiridina sustituidos y procesos para su preparación | |
| CL2017001289A1 (es) | Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr). | |
| ECSP19089214A (es) | Inhibidores de quinasa y usos de los mismos | |
| ECSP17030878A (es) | Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina | |
| MX2020004024A (es) | Derivados del colano para uso en el tratamiento y/o prevencion de enfermedades en las que intervienen el fxr y el tgr5/gpbar1. | |
| BR112016025132A2 (pt) | compostos polifluorados agindo como inibidores de tirosina quinase de bruton | |
| SV2018005775A (es) | Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2- carboxamida | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| MX2019015744A (es) | Composiciones farmaceuticas. | |
| CL2019000728A1 (es) | Formas cristalinas. | |
| MX379262B (es) | Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo. | |
| SV2018005776A (es) | Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxamida | |
| MX2017016619A (es) | Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos. | |
| MX367960B (es) | Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenil o)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificacion para su uso como principio activo farmaceutico. | |
| MX2016012784A (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| CL2019001053A1 (es) | Formulaciones farmacéuticas y métodos para prepararlas. | |
| MX2017002913A (es) | Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dim etilbenzofuran-3-carboxamida. | |
| CL2019002840A1 (es) | Formas cristalinas de (s)-afoxolaner. | |
| MX389099B (es) | Proceso para la preparación de 3-cloro-2-vinilfenilsulfonatos. | |
| CO2018002364A2 (es) | Una novedosa forma de isoxadifeno-etilo, un proceso para su preparación y uso de la misma |